Xencor, Inc.
Trispecific antibodies
Last updated:
Abstract:
The invention provides trispecific antibodies that co-engage CD3, CD8 and a tumor target antigen.
Status:
Grant
Type:
Utility
Filling date:
22 Dec 2015
Issue date:
1 Oct 2019